PPMD recently held a community webinar with Capricor Therapeutics, during which the company shared their most recent results from the Phase 3 HOPE-3 trial evaluating deramiocel (CAP-1002), Capricor’s investigational cell therapy for the treatment of Duchenne muscular dystrophy. The presentation included a review of the data, a discussion of planned next steps for FDA engagement and regulatory strategy, and a dedicated Q&A period.
Watch the Recording
The post Watch: Capricor Therapeutics — HOPE-3 Community Update (Webinar Recording) appeared first on Parent Project Muscular Dystrophy.